eISSN: 2084-9893
ISSN: 0033-2526
Dermatology Review/Przegląd Dermatologiczny
Current issue Archive About the journal Special Issues Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
2/2014
vol. 101
 
Share:
Share:
more
 
 
abstract:
Review paper

2012 European guideline on the diagnosis and treatment of gonorrhoea in adults*

Chris Bignell, Magnus Unemo

Przegl Dermatol 2014, 101, 168–178
Online publish date: 2014/05/21
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Rzeżączka jest ważnym problemem zdrowia publicznego na świecie. Szczególnym dylematem jest oporność na cefalosporyny o szerokim spektrum, obserwowana w ostatnich latach. W niniejszych zaleceniach przedstawiono rekomendacje dotyczące diagnostyki i leczenia rzeżączki w Europie. W porównaniu z poprzednimi zaleceniami z 2009 roku zalecenia z 2012 roku zostały uaktualnione; uwzględniają szersze wskazania do przeprowadzania badań; wprowadzają leczenie niepowikłanej rzeżączki dwoma antybiotykami (ceftriakson w dawce 500 mg i azytromycyna w dawce 2 g), gdy nie jest znana wrażliwość na antybiotyki; zalecają wykonanie testu potwierdzającego wyleczenie (ang. test of cure) we wszystkich przypadkach rzeżączki w celu zapewnienia eradykacji zakażenia i wykrycia możliwej antybiotykooporności oraz identyfikację, weryfikację i zgłaszanie przypadków niepowodzeń po stosowaniu rekomendowanej terapii. Osiągnięcie najwyższej jakości w przeprowadzaniu badań, diagnostyce, leczeniu i kontroli po leczeniu odgrywa podstawową rolę w kontroli nad szerzeniem się rzeżączki opornej na cefalosporyny i na wiele innych leków.
keywords:

gonorrhoea, European clinical guideline, management, Neisseria gonorrhoeae, diagnosis, antimicrobial resistance, antimicrobial treatment, antibiotic

references:
World Health Organization: Global incidence and prevalence of selected curable sexually transmitted infections – 2008. Geneva: World Health Organization; 2012. (http://www.who.int/reproductivehealth/publications/rtis/2008_STI_estimates.pdf) (dostęp 30 października 2012). 
European Centre for Disease Prevention and Control (ECDC): Sexually transmitted infections in Europe, 1990-2010. Stockholm, ECDC. 2012. (http://www.ecdc.europa.eu/en/publications/Publications/201206-Sexually-Transmitted-Infections-Europe-2010.pdf) (dostęp 30 października 2012). 
GRASP Steering Group: The gonococcal resistance to antimicrobials programme (GRASP) year 2010 report. London: Health Protection Agency 2011. (http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1316016752917) (dostęp 30 października 2012). 
Risley C.L., Ward H., Choudhury B., Bishop C.J., Fenton K.A., Spratt B.G. i inni: Geographical and demographic clustering of gonorrhoea in London. Sex Transm Infect 2007, 83, 481-487. 
Hook E.W. III, Handsfield H.H.: Gonococcal infections in the adult. [w:] K.K. Holmes, P.F. Sparling i inni (red.). Sexually transmitted diseases. 4 wyd. McGraw Hill, New York 2008, 627-645. 
Sherrard J., Barlow D.: gonorrhoea in men: clinical and diagnostic aspects. Genitourin Med 1996, 72, 422-426. 
Lewis D.A., Bond M., Butt K.D., Smith C.P., Shafi M.S., Murphy S.M.: A one-year survey of gonococcal infection seen in the genitourinary medicine department of a London district general hospital. Int J STD AIDS 1999, 10, 588-594. 
Barlow D., Phillips I.: gonorrhoea in women: diagnostic, clinical and laboratory aspects. Lancet 1978, 1, 761-764. 
Kent C.K., Chaw J.K., Wong W., Liska S., Gibson S., Hubbard G. i inni: Prevalence of rectal, urethral and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California 2003. Clin Infect Dis 2005, 41, 67-74. 
Peters R.P.H., Nijsten N., Mutsaers J., Jansen C.L., Morre S.A., van Leeuwen A.P.: Screening of oropharynx and anorectum increases prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infection in female STD clinic visitors. Sex Transm Dis 2011, 38, 783-787.
Bleich A.T., Sheffield J.S., Wendel G.D. Jr, Sigman A., Cunningham F.G.: Disseminated gonococcal infection in women. Obstet Gynecol 2012, 19, 597-602. 
O’Brien J.P., Goldenberg D.L., Rice P.A.: Disseminated gonococcal infection: a prospective analysis of 49 patients and a review of pathophysiology and immune mechanisms. Medicine 1983, 62, 395-406. 
Taylor S.N., DiCarlo R.P., Martin D.H.: Comparison of methylene blue/gentian violet stain to Gram’s stain for the rapid diagnosis of gonococcal urethritis in men. Sex Trans Dis 2011, 38, 995-996. 
Jephcott A.E.: Microbiological diagnosis of gonorrhoea. Genitourin Med 1997, 73, 245-252. 
Unemo M., Golparian D., Hestner A.: Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill 2011, 16, pii: 19792. 
Whiley D.M., Goire N., Lahra M.M., Donovan B., Limnios A.E., Nissen M.D. i inni: The ticking time bomb: escalating antibiotic resistance in Neisseria gonorrhoeae is a public health disaster in waiting. J Antimicrob Chemother 2012, 67, 2059-2061. 
Cook R.L., Hutchison S.L., Østergaard L., Braithwaite R.S., Ness R.B.: Non-invasive testing for Chlamydia trachomatis and Neisseria gonorrhoeae. Ann Intern Med 2005, 142, 914-925. 
Whiley D.M., Garland S.M., Harnett G., Lum G., Smith D.W., Tabrizi S.N. i inni: Exploring ‘best practice’ for nucleic acid detection of Neisseria gonorrhoeae. Sexual Health 2008, 5, 17-23. 
Harryman L., Scofield S., Macleod J., Carrington D., Williams O.M., Fernandes A. i inni: Comparative performance of culture using swabs transported in Amies medium and the Aptima Combo 2 nucleic acid amplification test in detection of Neisseria gonorrhoeae from genital and extragenital sites: a retrospective study. Sex Transm Infect 2012, 88, 127-131. 
Van Dyck E., Ieven M., Pattyn S., Van Damme L., Laga M.: Detection of Chlamydia trachomatis and Neisseria gonorrhoeae by enzyme immunoassay, culture and three nucleic acid amplification tests. J Clin Microbiol 2001, 39, 1751-1756. 
Van der Pol B., Ferrero D.V., Buck-Barrington L., Hook E.W. 3rd, Lenderman C., Quinn T.C. i inni: Multicenter evaluation of the BDProbeTec ET system for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine specimens, female endocervical and male urethral swabs. J Clin Microbiol 2001, 39, 1008-1016. 
Moncada J., Schachter J., Hook E.W. 3rd, Ferrero D., Gaydos C., Quinn T. i inni: The effect of urine testing in evaluations of the sensitivity of the Gen-Probe APTIMA Combo 2 Assay on endocervical swabs for Chlamydia trachomatis and Neisseria gonorrhoeae. Sex Trans Dis 2004, 31, 273-277. 
Chernesky M.A., Martin D.H., Hook E.W., Willis D., Jordan J., Wang S. i inni: Ability of new APTIMA CT and APTIMA GC Assays to detect Chlamydia trachomatis and Neisseria gonorrhoeae in male urine and urethral swabs. J Clin Microbiol 2005, 43, 127-131. 
Schachter J., Chernesky M.A., Willis D.E., Fine P.M., Martin D.H., Fuller D. i inni: Vaginal swabs are the specimens of choice when screening for Chlamydia trachomatis and Neisseria gonorrhoeae: results from a multicenter evaluation of the APTIMA assays for both infections. Sex Trans Dis 2005, 32, 725-728. 
Ison C.: GC NAATs: is the time right? Sex Transm Infect 2006, 82, 515. 
Association of Public Health Laboratories: Laboratory diagnostic testing for Chlamydia trachomatis and Neisseria gonorrhoeae. Expert consultation meeting summary report; January 13-15, 2009; Atlanta, GA. Silver Spring, MD: Association of Public Health Laboratories; 2009. (http://www.aphl.org/aphlprograms/infectious/std/documents/ctgclabguidelinesmeetingreport.pdf) (dostęp 30 października 2012). 
Smith D.W., Tapsall J.W., Lum G.: Guidelines for the use and interpretation of nucleic acid detection tests for Neisseria gonorrhoeae in Australia: a position paper on behalf of the Public Health Laboratory Network. Commun Dis Intell 2005, 29, 358-365. 
Department of Health, Health Protection Agency and BASHH Feb 2010. Guidance for gonorrhoea testing in England and Wales. (Available from: http://www.bashh.org/guidelines (2010 HPA guidance on gonorrhoea testing in England & Wales) (dostęp 30 października 2012). 
Page-Shafer K., Graves A., Kent C., Bals J.E., Zapitz V.M., Klausner J.D.: Increased sensitivity of DNA amplification testing for the detection of pharyngeal gonorrhoea in men who have sex with men. Clin Infect Dis 2002, 34, 173-176. 
McNally L.P., Templeton D.J., Jin F., Grulich A.E., Donovan B., Whiley D.M. i inni: Low positive predictive value of a nucleic acid amplification test for nongenital Neisseria gonorrhoeae infection in homosexual men. Clin Infect Dis 2008, 47, e25-e27. 
Schachter J., Moncada J., Liska S., Shayevich C., Klausner J.D.: Nucleic acid amplification tests in the diagnosis of chlamydial and gonococcal infections in the oropharynx and rectum in men who have sex with men. Sex Trans Dis 2008, 35, 637-642. 
Ota K.V., Tamari I.E., Smieja M., Jamieson F., Jones K.E., Towns L. i inni: Detection of Neisseria gonorrhoeae and Chlamydia trachomatis in pharyngeal and rectal specimens using the BD Probetec ET system, the Gen-Probe Aptima Combo 2 assay and culture. Sex Trans Infect 2009, 85, 182-186. 
Alexander S.: The challenges of detecting gonorrhoea and chlamydia in rectal and pharyngeal sites: could we, should we, be doing more? Sex Trans Infect 2009, 85, 159-160. 
Bachmann L.H., Johnson R.E., Cheng H., Markowitz L., Papp J.R., Palella F.J. Jr i inni: Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae and Chlamydia trachomatis rectal infections. J Clin Microbiol 2010, 48, 1827-1832. 
Mimiaga M.J., Helms D.J., Reisner S.L., Grasso C., Bertrand T., Mosure D.J. i inni: Gonococcal, chlamydia, and syphilis infection positivity among MSM attending a large primary care clinic, Boston, 2003 to 2004. Sex Transm Dis 2009, 36, 507-511. 
Palmer H., Mallinson H., Wood R.L., Herring A.J.: Evaluation of the specificities of five DNA amplification methods for the detection of Neisseria gonorrhoeae. J Clin Microbiol 2003, 41, 835-837. 
Tabrizi S.N., Unemo M., Limnios A.E., Hogan T.R., Hjelmevoll S.O., Garland S.M. i inni: Evaluation of six commercial nucleic acid amplification tests for the detection of Neisseria gonorrhoeae and other Neisseria species. J Clin Microbiol 2011, 49, 3610-3615. 
Lavelle S.J., Jones K.E., Mallinson H., Webb A.M.C.: Finding, confirming, and managing gonorrhea in a population screened for chlamydia using the Gen-Probe Aptima Combo2 assay. Sex Trans Infect 2006, 82, 221-224. 
Jin F., Prestage G.P., Mao L., Kippax S.C., Pell C.M., Donovan B. i inni: Incidence and risk factors for urethral and anal gonorrhoea and chlamydia in a cohort of HIV-negative homosexual men: the health in men study. Sex Trans Infect 2007, 83, 113-119. 
Tapsall J.W., Ndowa F., Lewis D.A., Unemo M.: Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 2009, 7, 821-834. 
European Centre for Disease Prevention and Control (ECDC): Gonococcal antimicrobial susceptibility surveillance in Europe 2010. Stockholm: ECDC 2012. (http://ecdc.europa.eu/en/publications/Publications/1206-Gonococcal-AMR.pdf) (dostęp 30 października 2012). 
Chisholm S., Mouton J., Lewis D., Nichols T., Ison C., Livermore D.: Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J Antimicrob Chemother 2010, 65, 2141-2148. 
Ohnishi M., Golparian D., Shimuta K., Saika T., Hoshina S., Iwasaku K. i inni: Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea? Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011, 55, 3538-3345. 
Unemo M., Golparian D., Nicholas R., Ohnishi M., Gallay A., Sednaoui P.: High-level cefixime- and ceftriaxone-resistant N. gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012, 56, 1273-1280. 
Unemo M., Golparian D., Syversen G., Vestrheim D.F., Mol H.: Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill 2010, 15, pii: 19721. 
Ison C.A., Hussey J., Sankar K.N., Evans J., Alexander S.: gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill 2011, 16, pii: 19833. 
Unemo M., Golparian D., Stary A., Eigentler A.: First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria. Euro Surveill 2011, 16, pii: 19998. 
Unemo M., Golparian D., Potočnik M., Jeverica S.: Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011. Euro Surveill 2012, 17, pii: 20200. 
Forsyth S., Penney P., Rooney G.: Cefixime-resistant Neisseria gonorrhoeae in the UK: a time to reflect on practice and recommendations. Int J STD AIDS 2011, 22, 296-297. 
World Health Organization (WHO), Department of Reproductive Health and Research: Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. Geneva: WHO; 2012. p. 1-36. (http://whqlibdoc.who.int/publications/2012/9789241503501_eng.pdf) (dostęp 30 października 2012). 
European Centre for Disease Prevention and Control (ECDC): Response plan to control and manage the threat of multidrug-resistant gonorrhoea in Europe. Stockholm: ECDC; 2012. p. 1-23. (http://www.ecdc.europa.eu/en/publications/Publications/1206-ECDC-MDR-gonorrhoea-response-plan.pdf) (dostęp 30 października 2012). 
Centers for Disease Control and Prevention (CDC): Cephalosporin-Resistant Neisseria gonorrhoeae Public Health Response Plan. 2012. p. 1-43. (http://www.cdc.gov/std/gonorrhea/default.htm) (dostęp 30 października 2012). 
Furuya R., Nakayama H., Kanayama A., Saika T., Iyoda T., Tatewaki M. i inni: In vitro synergistic effects of double combinations of beta-lactams and azithromycin against clinical isolates of Neisseria gonorrhoeae. J Infect Chemotherapy 2006, 12, 172-176. 
Sathia L., Ellis B., Phillip S., Winston A., Smith A.: Pharyngeal gonorrhoea – is dual therapy the way forward? Int J STD AIDS 2007, 18, 647-648. 
Golden M., Kerani R., Shafii T., Whittington W., Holmes K.: Does azithromycin co-treatment enhance the efficacy of oral cephalosporins for pharyngeal gonorrhea? Presented at: 18th International Society for STD Research (ISSTDR) Conference, London, UK, June 2009. 
Moran J.S., Levine W.C.: Drugs of choice in the treatment of uncomplicated gonococcal infection. Clin Infect Dis 1995, 20 (Suppl. 1), S47-S65. 
Bignell C., Fitzgerald M.; BASHH Guideline Development Group: UK national guideline for the management of gonorrhoea in adults, 2011. Int J STD AIDS 2011, 22, 541-547. 
Centers for Disease Control and Prevention (CDC): Sexually Transmitted Diseases Treatment Guidelines, 2010. MMWR 2010, 59(No. RR-12), 49-55. 
Centers for Disease Control and Prevention (CDC): Update to CDC’s Sexually Transmitted Diseases Treatment Guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012, 61, 590-594. 
Newman L.M., Moran J.S., Workowski K.A.: Update on the management of gonorrhoea in adults in the United States. Clin Infect Dis 2007, 44, S84-S101. 
Ison C.A., Mouton J.W., Jones K., Fenton K.A., Livermore D.A.: Which cephalosporin for gonorrhoea? Sex Transm Infect 2004, 80, 386-388. 
Moran J.S.: Ciprofloxacin for gonorrhea – 250 mg or 500 mg? Sex Trans Dis 1996, 23, 165-167. 
Handsfield H.H., Dalu Z.A., Martin D.H., Douglas J.M. Jr, McCarty J.M., Schlossberg D.: Multicenter trial of single-dose azithromycin vs ceftriaxone in the treatment of uncomplicated gonorrhoea. Sex Trans Dis 1994, 21, 107-111. 
Bignell C., Garley J.: Azithromycin in the treatment of infection with Neisseria gonorrhoeae. Sex Transm Infect 2010, 86, 422-426. 
Palmer H.M., Young H., Winter A., Dave J.: Emergence and spread of azithromycin-resistant Neisseria gonorrhoeae in Scotland. J Antimicrob Chemother 2008, 62, 490-494. 
Chisholm S.A., Neal T.J., Alawattegama A.B., Birley H.D.L., Howe R.A., Ison C.A.: Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales. J Antimicrob Chemother 2009, 64, 353-358. 
Chisholm S.A., Dave J., Ison C.A.: High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. Antimicrob Agents Chemother 2010, 54, 3812-3816. 
Starnino S., Stefanelli P.; Neisseria gonorrhoeae Italian Study Group: Azithromycin-resistant Neisseria gonorrhoeae strains recently isolated in Italy. J Antimicrob Chemother 2009, 63, 1200-1204. 
Young H., Moyes A., McMillan A.: Azithromycin and erythromycin resistant Neisseria gonorrhoeae following treatment with azithromycin. Int J STD AIDS 1997, 8, 299-302. 
Tapsall J.W., Schultz T.R., Limnios E.A., Donovan B., Lum G., Mulhall B.P.: Failure of azithromycin therapy in gonorrhoea and discorrelation with laboratory parameters. Sex Trans Dis 1998, 25, 505-508. 
Ota K.V., Fisman D.N., Tamari I.E., Smieja M., Ng L.K., Jones K.E. i inni: Incidence and treatment outcomes of pharyngeal Neisseria gonorrhoeae and Chlamydia trachomatis infections in men who have sex with men: a 13-year retrospective cohort study. Clin Infect Dis 2009, 48, 1237-1243. 
Moran J.S.: Treating uncomplicated Neisseria gonorrhoeae infections: is the anatomic site of infection important? Sex Transm Dis 1995, 22, 39-47. 
Ross J.D.C., Lewis D.A.: Cephalosporin resistant Neisseria gonorrhoeae: time to consider gentamicin? Sex Transm Infect 2012, 88, 6-8. 
Dowell D., Kirkcaldy R.D.: Effectiveness of gentamicin for gonorrhoea treatment: systematic review and meta-analysis. Sex Transm Infect 2012, 88, 589-594. 
Brown L.B., Krysiak R., Kamanga G., Mapanje C., Kanyamula H., Banda B. i inni: Neisseria gonorrhoeae antimicrobial susceptibility in Lilongwe, Malawi, 2007. Sex Transm Dis 2010, 37, 169-172. 
Chisholm S.A., Quaye N., Cole M.J., Fredlund H., Hoffmann S., Jensen J.S. i inni: An evaluation of gentamicin susceptibility of Neisseria gonorrhoeae isolates in Europe. J Antimicrob Chemother 2011, 66, 592-595. 
Ramus R.M., Sheffield J.S., Mayfield J.A., Wendel G.D.: A randomised trial that compared oral cefixime and intramuscular ceftriaxone for the treatment of gonorrhoea in pregnancy. Am J Obstet Gynecol 2001, 185, 629-632. 
Sandoz Limited. SPC on Azithromycin 28/09/2010. (http://www.medicines.org.uk/EMC/medicine/21720/SPC/Azithromycin+500mg+Tablets/#PREGNANCY) (dostęp 30 października 2012). 
Pichichero M.E., Casey J.R.: Safe use of selected cephalosporins in penicillin-allergic patients: a meta-analysis. Otolaryngol Head Neck Surg 2007, 136, 340-347. 
Yates A.B.: Management of patients with a history of allergy to beta-lactam antibiotics. Am J Med 2008, 121, 572-576. 
Wise C.M., Morris C.R., Wasilauskas B.L., Salzer W.L.: Gonococcal arthritis in an era of increasing penicillin resistance. Presentations and outcomes in 41 recent cases (1985-1991). Arch Intern Med 1994, 154, 2690-2695. 
Thompson S.E.: Treatment of disseminated gonococcal infections. Sex Transm Dis 1979, 6 (Suppl. 1), 181-184. 
Hjelmevoll S.O., Olsen M.E., Sollid J.U., Haaheim H., Melby K.K., Moi H. i inni: Appropriate time for test-of-cure when diagnosing gonorrhoea with a nucleic acid amplification test. Acta Derm Venereol 2012, 92, 316-319. 
Bachmann L.H., Desmond R.A., Stephens J., Hughes A., Hook E.W. 3rd.: Duration of persistence of gonococcal DNA detected by ligase chain reaction in men and women following recommended therapy for uncomplicated gonorrhea. J Clin Microbiol 2002, 40, 3596-3601.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe